The University is keen to promote technology transfer by licensing IP to third parties. We have several technologies which are currently available for licensing. For some licences the University's Essential Medicines Statement (PDF, 78kB) may be applicable. Please select a category below:
The opportunities listed below are very recent developments which require further technical and business development. Typically, work is continuing in the laboratory to refine the technology or demonstrate the effectiveness of the invention for commercialisation. We are very interested in talking to potential partners to discuss the current state of the work with the respective research teams. In most cases we have filed a provisional patent application and are able to discuss details without an NDA.
|Composites||1909||Aligned Short Fibre Composites|
|Photonics||1820||On-chip Single Photon Source|
|890||Human Podocyte cell line|
|1528||Novel Product for the Alleviation of Symptom 'flare-up' in Chronic Intestinal Disease|
|1976||New materials for targeted vaccine delivery|
|Wireless||1736||Channel signature modulation|
|Composites||1869||Pick and place end effector|
|Composites||1537||Morphing air scoop|
|Electrical||2441||Zero Power Always Awake Signal Monitor|
|Mechanical||1119||Optimal micromixers for microfluidics|
|Photonics||1796||Twisted light source|
|Physics||1656||Low work function diamond surface|
|Chemistry||1976||New materials for targeted vaccine delivery|
|Radiotherapy||1529||Real-time dosimetry system for real-time verification of modulated radiotherapy treatments|
Some of Bristol's software and copyright materials are available through ready-to-sign licences. These licences have standard terms and conditions, making the licensing rapid and cost effective for companies or individual licensees. We are happy to consider alternative licensing arrangements but please note that the costs of bespoke licences may be passed on to the licensee.
The level of support and maintenance available for each software package will be listed in the individual licence.
If you would like to increase the number of authorised users for an existing software package, extend the licence to a different field or territory or renew an existing licence, please contact Meg Joyce at email@example.com.
If the standard licence for any particular software or copyright material does not meet your needs, please contact Meg Joyce at firstname.lastname@example.org to discuss alternative arrangements.
A tissue engineering group at the university has developed a treatment for stem cells used to create cartilage which reduces undesirable creation of bone-like tissue
If you would like further information about any of the technologies listed, or you would like to discuss further licensing opportunities, please contact our Research Commercialisation team.